François‐Xavier Mahon

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

Medicine, Hematology, Pharmacology +4

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 611 citations · Full text

Medicine, Oncology, Pharmacology +11

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stéphane Picard, Karine Titier, Gabriel Étienne et al. · Blood · 2006 · 604 citations · Full text

Life Sciences, Hematology, Oncology +13

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

François‐Xavier Mahon, Françis Belloc, Valérie Lagarde et al. · Blood · 2003 · 538 citations · Full text

Medicine, Molecular Biology, Oncology +11

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Philippe Rousselot, Françoise Huguet, Delphine Réa et al. · Blood · 2006 · 530 citations

Pharmacy, Hematology, Pharmacotherapy +3